Sage Therapeutics, Inc., (NASDAQ:SAGE) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET
Company Participants
Ashley Kaplowitz - Vice President of Investor Relations and Capital Markets
Barry Greene - Chief Executive Officer
Chris Benecchi - Chief Business Officer
Laura Gault - Chief Medical Officer
Kimi Iguchi - Chief Financial Officer
Mike Quirk - Chief Scientific Officer
Conference Call Participants
Salveen Richter - Goldman Sachs
Anupam Rama - JPMorgan
Yasmeen Rahimi - Piper Sandler
Paul Matteis - Stifel
Jay Olson - Oppenheimer.
Ritu Baral - TD Cowen
Brian Abrahams - RBC Capital Markets
Laura Chico - Wedbush Securities
David Hoang - Citigroup
Tazeen Ahmad - Bank of America
George Farmer - Scotiabank
Vikram Purohit - Morgan Stanley
Sumant Kulkarni - Canaccord
Uy Ear - Muziho
Douglas Tsao - H.C. Wainwright
Operator
Good afternoon. Welcome to Sage Therapeutics Second Quarter 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Sage's website at sagerx.com. This call is the property of Sage Therapeutics and recording, reproduction, or transmission of this call without the expressed written consent of Sage Therapeutics is strictly prohibited. Please note that this call is being recorded.
I would now like to introduce Ashley Kaplowitz, Vice President of Investor Relations and Capital Markets at Sage.
Ashley Kaplowitz
Good morning, and thank you for joining Sage Therapeutics' second quarter 2024 financial results conference call. Before we begin, I encourage everyone to go to the Investors & Media section of our website at sagerx.com, where you can find the press release and slides related to today's call.
I would like to point out that, we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please review the risk factors discussed in today's press release and in our SEC filings for additional details.
We will begin the call with prepared remarks by Barry Greene, our Chief Executive Officer, who will provide an overview of our progress during the second quarter of 2024. Our Chief Business Officer, Chris Benecchi will provide an update on the ongoing commercialization of ZURZUVAE in postpartum depression or PPD. Laura Gault, our Chief Medical Officer who will review development activities across our programs. We will then be joined by Kimi Iguchi, our Chief Financial Officer, who will review our financial results from the second quarter of 2024. Mike Quirk, our Chief Scientific Officer will be available for questions during the Q&A portion of the call.